tiprankstipranks
Corcept Therapeutics Inc. (GB:0I3Q)
LSE:0I3Q
UK Market

Corcept Therapeutics Stock Analysis & Ratings

GB:0I3Q Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$18.92
VolumeN/A
Average Volume (3M)92.00
Market Cap$2.01B
P/E RatioN/A
Beta1.09
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)0.00


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

GB:0I3Q FAQ

What was Corcept Therapeutics’s price range in the past 12 months?
Corcept Therapeutics lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Corcept Therapeutics’s market cap?
    Corcept Therapeutics’s market cap is $2.01B.
      What is Corcept Therapeutics’s price target?
      The average price target for Corcept Therapeutics is $29.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $29.00 ,the lowest forecast is $29.00. The average price target represents 53.28% Increase from the current price of $18.92.
        What do analysts say about Corcept Therapeutics?
        Corcept Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Corcept Therapeutics’s upcoming earnings report date?
          Corcept Therapeutics’s upcoming earnings report date is Aug 03, 2022 which is in 78 days.
            How were Corcept Therapeutics’s earnings last quarter?
            Corcept Therapeutics released its earnings results on May 05, 2022. The company reported $0.2 earnings per share for the quarter, missing the consensus estimate of $0.232 by -$0.032.
              Is Corcept Therapeutics overvalued?
              According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
                Does Corcept Therapeutics pay dividends?
                Corcept Therapeutics does not currently pay dividends.
                What is Corcept Therapeutics’s EPS estimate?
                Corcept Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Corcept Therapeutics have?
                Corcept Therapeutics has 106,250,000 shares outstanding.
                  What happened to Corcept Therapeutics’s price movement after its last earnings report?
                  Corcept Therapeutics reported an EPS of $0.2 in its last earnings report, missing expectations of $0.232. Following the earnings report the stock price went down -7.568%.
                    Which hedge fund is a major shareholder of Corcept Therapeutics?
                    Among the largest hedge funds holding Corcept Therapeutics’s share is Royce & Associates LLC. It holds Corcept Therapeutics’s shares valued at 6M.

                      ---

                      Corcept Therapeutics Stock Analysis

                      The Corcept Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Corcept Therapeutics Inc.

                      Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Novartis
                      Cyclacel Pharmaceuticals
                      Viking Therapeutics
                      Lexicon Pharmaceuticals
                      BioMarin Pharmaceutical

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis